FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation

Blood

Volumn 125, Issue 12, 2015, Pages 1936-1947

  Oellerich, Thomas ^a,b   Mohr, Sebastian ^a   Corso, Jasmin ^c   Beck, Julia ^d   Döbele, Carmen ^a   Braun, Helene ^b   Cremer, Anjali ^a   Münch, Silvia ^a   Wicht, Johannes ^b   Oellerich, Mark F ^a   Bug, Gesine ^a   Bohnenberger, Hanibal ^e   Perske, Christina ^e   Schütz, Ekkehard ^d   Urlaub, Henning ^c,f   Serve, Hubert ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^d Chronix Biomedical Inc   (United States)

^e UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^f UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE; CD135 ANTIGEN; FLT3 LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; STAT5 PROTEIN; TOLL LIKE RECEPTOR 9; AGAMMAGLOBULINAEMIA TYROSINE KINASE; FLT3 PROTEIN, HUMAN; PROTEIN TYROSINE KINASE; STAT5A PROTEIN, HUMAN; TLR9 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; TYROSINE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL EXPANSION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; BONE MARROW CELL; CELL CYCLE; CHEMISTRY; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; TUMOR CELL LINE; YOUNG ADULT;

ADULT; APOPTOSIS; BONE MARROW CELLS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOID, ACUTE; MASS SPECTROMETRY; MIDDLE AGED; NF-KAPPA B; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TOLL-LIKE RECEPTOR 9; TUMOR SUPPRESSOR PROTEINS; TYROSINE; YOUNG ADULT;

EID: 84925379439     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-06-585216     Document Type: Article

References (22)

1. Miller CA, Wilson RK, Ley TJ. Genomic landscapes and clonality of de novo AML. N Engl J Med. 2013;369(15):1473.
2. Chu SH, Heiser D, Li L, et al. FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm. Cell Stem Cell. 2012;11(3):346-358.
3. Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013;31(29):3681-3687.
4. Sexauer A, Perl A, Yang X, et al. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood. 2012;120(20):4205-4214.
5. Hahn CK, Berchuck JE, Ross KN, et al. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell. 2009;16(4):281-294.
6. Oellerich T, Oellerich MF, Engelke M, et al. β2 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis. Blood. 2013;121(19):3889-3899.
7. Satterthwaite AB, Witte ON. The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev. 2000;175:120-127.
8. Rickert RC. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol. 2013;13(8):578-591.
9. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-516.
10. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
11. Khan WN, Alt FW, Gerstein RM, et al. Defective B cell development and function in Btk-deficient mice. Immunity. 1995;3(3):283-299.
12. Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood. 2014;123(8):1229-1238.
13. Selbach M, Mann M. Protein interaction screening by quantitative immunoprecipitation combined with knockdown (QUICK). Nat Methods. 2006;3(12):981-983.
14. Ormsby T, Schlecker E, Ferdin J, et al. Btk is a positive regulator in the TREM-1/DAP12 signaling pathway. Blood. 2011;118(4):936-945.
15. Kubo T, Uchida Y, Watanabe Y, et al. Augmented TLR9-induced Btk activation in PIR-B-deficient B-1 cells provokes excessive autoantibody production and autoimmunity. J Exp Med. 2009;206(9):1971-1982.
16. Vijayan V, Baumgart-Vogt E, Naidu S, Qian G, Immenschuh S. Bruton's tyrosine kinase is required for TLR-dependent heme oxygenase-1 gene activation via Nrf2 in macrophages. J Immunol. 2011;187(2):817-827.
17. Mercurio F, Zhu H, Murray BW, et al. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science. 1997;278(5339):860-866.
18. Mizuki M, Schwable J, Steur C, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood. 2003;101(8):3164-3173.
19. Smith CC, Wang Q, Chin CS, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012;485(7397):260-263.
20. Serve H, Krug U, Wagner R, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol. 2013;31(25):3110-3118.
21. Krysko DV, Kaczmarek A, Krysko O, et al. TLR-2 and TLR-9 are sensors of apoptosis in a mouse model of doxorubicin-induced acute inflammation. Cell Death Differ. 2011;18(8):1316-1325.
22. Puissant A, Fenouille N, Alexe G, et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 2014;25(2):226-242.